Changes in structural and functional retinal features resulting from the effect of a long-acting steroid in serous PED associated with AMD: a 36-month follow-up study
T.B. Kustryn, MD
I.O. Nasinnyk, Cand Sc (Med)
A.A. Nevskaya, MD
O.S. Zadorozhnyy, Cand Sc (Med)
A.R. Korol, Dr Sc (Med)
Filatov Institute of Eye Diseases and Tissue Therapy
Background: Although a variety of approaches are available for treating retinal pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD), no unified methodology has yet been approved and/or overwhelmingly favored.
Purpose: To investigate the effect of a long-acting steroid on the structural and functional RPE features in serous PED associated with AMD in long-term follow-up study, and to improve the efficacy of treatment of this disorder through the use of steroid therapy based on the findings of this investigation.
Materials and Methods: Fifty-two patients (54 eyes) with serous PED associated with AMD were followed up for 36 months. They were divided into subtenon and intravitreal groups comprising 30 patients (32 eyes) and 22 patients (22 eyes), respectively, and treated with 0.5 ml (40 mg) subtenon triamcinolone acetonide (TA) suspension and 0.1 ml (4 mg) intravitreal TA crystals, respectively, as needed.
Results: We found significant reductions in the height and length of PED in the intravitreal group (from 486 (SD 187) µm to 256 (SD 139) µm, P = 0.005; and from 1859 (SD 911) µm to 1112 (SD 451) µm, P = 0.04, respectively) and in the subtenon group (from 446 (SD 199) µm to 231 (SD 107) µm, P = 0.0001; and from 2055 (SD 587) µm to 1423 (SD 465) µm, P = 0.02, respectively). In study eyes, the visual acuity remained stable throughout the 36-month follow-up period, irrespective of the route of administration of TA.
Conclusion: The use of subtenon and intravitreal TA in serous PED associated with AMD is efficacious for maintaining the anatomical structure of the retina.
Key words: serous retinal pigment epithelial detachment, age-related macular degeneration, subtenon and intravitreal injections, triamcinolone acetonide
1.Pasyechnikova NV, Korol AR. [Clinical classification and tactics of management of patients with age related macular degeneration]. Oftalmol Zh. 2010;2:38-41 Russian
2.Gomez-Ulla F, Gonzalez F, Abelenda D, et al. Diode laser photocoagulation of choroidal neovascularization associated with retinal pigment epithelial detachment. Acta Ophthalmol Scand. 2001 Feb;79(1):39-44
3.Axer-Siegel R, Ehrlich R, Rosenblatt I, et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelial detachment in age-related macular degeneration. Arch Ophthalmol. 2004 Apr;122(4):453-9
5.Boguszakova´ J, Dubska´ Z. Tears of the retinal pigment epithelium. Cesk Slov Oftalmol. 2001;57:367-71
6.Panos GD, Gatzioufas Z, Petropoulos IK, et al. Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration. Drug Des Develd Ther. 2013 Jul 10;7:565-9
7.Kook D, Wolf A, Neubauer AS, et al. [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress]. Ophthalmologe. 2008 Feb;105(2):158-64 German
8.Suk SA, Saksonov SG, Kuznetsova TA. [Use of posterior subtenon injection combined with transpupillary thermotherapy for subfoveal choroidal neovascularization associated with age-related macular degeneration]. Oftalmol Zh. 2008;3:19-22 Russian
9.Axer-Siegel R, Ehrlich R, I. Avisar I, et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelial detachment. Ophthalmic Surg Lasers Imaging. 2006 Nov-Dec;37(6):455-61
10.el Matri L, Chebil A, Kort F, et al. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):779-84
11.Levitska GV, Putienko AA. Abdulkhadi Mukhammad. [Features of changes in IL-6 and TNF in patients with RRD associated with vitreous detachment after intravitreal injection of triamcinolone acetonide]. [Issues of environmental and medical genetics and clinical ophthalmology]. 2005 5:61-70 Russian
12.Ozdemir H, Karacorlu S, Alacali N, et al. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye. 2005;19:382–6
13.Ozdek S, Deren YT, Gurelik G, et al. Posterior subtenon triamcinolone, intravitreal triamcinolone and grid laser photocoagulation for the treatment of macular edema in branch retinal vein occlusion. Ophthalmic Res. 2008;40(1):26-3
14.Toda J, Fukushima H, Kato S. Injection of triamcinolone acetonide into the posterior sub-tenon capsule for treatment of diabetic macular edema. Retina. 2007 Jul-Aug;27(6):764-9
15.Pasyechnikova NV, Naumenko VA, Korol AR, et al. Serous Pigment epithelial detachment Associated with Age-Related Macular Degeneration: A Possible Treatment Approach. Med Hypothesis Discov Innov Ophthalmol. 2012 Winter;1(4):72-5
16.Barondes MJ, Pagliarinit S, Chisholm IH, et al. Controlled trial of laser photocoagulation of pigment epithelial detachments in the elderly: 4 year review. Br J Ophthalmol. 1992;76(1):5-7
17.Moorfields macular study group. Retinal pigment epithelial detachments in the elderly: a controlled trial of argon laser photocoagulation. Br J Ophthalmology. 1982 Jan; 66(1): 1–16
18.de Jong PT. Laser treatment of central serous chorioretinopathy, of pigment epithelial detachments and of subretinal neovascularizations in senile disciform macular degeneration. Bull Soc Belge Ophtalmol. 1981;197:55-61
19.Ho PC, Namperumalsamy P, Pruett RC. Photocoagulation of serous detachments of the retinal pigment epithelium in patients with senile macular disease. Ann Ophthalmol. 1984 Mar;16(3):213-8
20.Pece A, Isola V, Vadala M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization associated with retinal pigment epithelial detachment in age-related macular degeneration. Retina. 2007 Mar;27(3):342-8
21.Ladas ID, Kotsolis AI, Rouvas AA, et al. Efficacy of photodynamic therapy in the management of occult choroidal neovascularization associated with serous pigment epithelial detachment. Ophthalmologica. 2007;221(5):313-9
22.Lommatzsch A, Heimes B, Gutfleisch M, et al. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye (Lond). 2009 Dec;23(12):2163-8
23.Ritter M, Bolz M, Sacu S, et al.Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye (Lond). 2010 Jun;24(6):962-8
24.Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007 Jan;245(1):68-73
25.Huddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. Br J Ophthalmol. 2002 Jun;86(6):663-9
26.Pauleikhoff D, Löffert D, Spital G, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol. 2002 Jul;240(7):533-8
27.Siqueira RC, dos Santos WF, Scott IU, et al. Neuroprotective effects of intravitreal triamcinolone acetonide and dexamethasone implant in rabbit retinas after pars plana vitrectomy and silicone oil injection. Retina. 2015 Feb;35(2):364-70
28.Miura Y, Roider J. Triamcinolone acetonide prevents oxidative stress-induced tight junction disruption of retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):641-9